p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling

dc.contributor.authorKundu, Debjyoti
dc.contributor.authorKennedy, Lindsey
dc.contributor.authorZhou, Tianhao
dc.contributor.authorEkser, Burcin
dc.contributor.authorMeadows, Vik
dc.contributor.authorSybenga, Amelia
dc.contributor.authorKyritsi, Konstantina
dc.contributor.authorChen, Lixian
dc.contributor.authorCeci, Ludovica
dc.contributor.authorWu, Nan
dc.contributor.authorWu, Chaodong
dc.contributor.authorGlaser, Shannon
dc.contributor.authorCarpino, Guido
dc.contributor.authorOnori, Paolo
dc.contributor.authorGaudio, Eugenio
dc.contributor.authorAlpini, Gianfranco
dc.contributor.authorFrancis, Heather
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-02-22T14:58:41Z
dc.date.available2024-02-22T14:58:41Z
dc.date.issued2023
dc.description.abstractBackground and aims: NAFLD is characterized by steatosis, hepatic inflammation, and fibrosis, which can develop into NASH. Patients with NAFLD/NASH have increased ductular reaction (DR) and biliary senescence. High fat/high cholesterol diet feeding increases biliary senescence, DR, and biliary insulin-like growth factor-1 (IGF-1) expression in mice. p16/IGF-1 converges with fork-head box transcription factor O1 (FOXO1) through E2F1. We evaluated p16 inhibition on NAFLD phenotypes and biliary E2F1/FOXO1/IGF-1 signaling. Approach and results: 4-week wild-type (C57BL/6J) male mice were fed a control diet (CD) or high fat/high cholesterol diet and received either p16 or control Vivo Morpholino (VM) by tail vein injection 2× during the 16th week of feeding. We confirmed p16 knockdown and examined: (i) NAFLD phenotypes; (ii) DR and biliary senescence; (iii) serum metabolites; and (iv) biliary E2F1/FOXO1/IGF-1 signaling. Human normal, NAFLD, and NASH liver samples and isolated cholangiocytes treated with control or p16 VM were evaluated for p16/E2F1/FOXO1/IGF-1 signaling. p16 VM treatment reduced cholangiocyte and hepatocyte p16. In wild-type high fat/high cholesterol diet mice with control VM, there were increased (i) NAFLD phenotypes; (ii) DR and biliary senescence; (iii) serum metabolites; and (iv) biliary E2F1/FOXO1/IGF-1 signaling; however, p16 VM treatment reduced these parameters. Biliary E2F1/FOX-O1/IGF-1 signaling increased in human NAFLD/NASH but was blocked by p16 VM. In vitro , p16 VM reduced biliary E2f1 and Foxo1 transcription by inhibiting RNA pol II binding and E2F1 binding at the Foxo1 locus, respectively. Inhibition of E2F1 reduced biliary FOXO1 in vitro. Conclusion: Attenuating hepatic p16 expression may be a therapeutic approach for improving NAFLD/NASH phenotypes.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationKundu D, Kennedy L, Zhou T, et al. p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling. Hepatology. 2023;78(1):243-257. doi:10.1097/HEP.0000000000000307
dc.identifier.urihttps://hdl.handle.net/1805/38617
dc.language.isoen_US
dc.publisherWolters Kluwer
dc.relation.isversionof10.1097/HEP.0000000000000307
dc.relation.journalHepatology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectNASH
dc.subjectDuctular reaction
dc.subjectInflammation
dc.subjectSenescence
dc.subjectMetabolites
dc.titlep16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1909404.pdf
Size:
4.53 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: